Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort studyMinggui Wang, H. R. Cross, Hainv Gao et al.|The Lancet Infectious Diseases|2021Cited by 338
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort studyDavid van Duin, Robert A. Bonomo, César A. Arias et al.|The Lancet Infectious Diseases|2020Cited by 328
Emerging Plasmid-Mediated Quinolone Resistance Associated with the <i>qnr</i> Gene in <i>Klebsiella pneumoniae</i> Clinical Isolates in the United StatesMinggui Wang, David C. Hooper, Daniel F. Sahm et al.|Antimicrobial Agents and Chemotherapy|2004Cited by 239
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, Surbhi Malhotra‐Kumar, José Miguel Cisneros et al.|The Lancet Infectious Diseases|2024Cited by 98
2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT StudyYehuda Carmeli, Joseph W. Chow, Jose-Miguel Cisneros et al.|Open Forum Infectious Diseases|2023Cited by 25